FDA Grants Priority Review for BIZENGRI Supplement by Merus N.V.
The FDA has granted priority review for the supplemental application of BIZENGRI (ZENOCUTUZUMAB-ZBCO) submitted by Merus N.V.
Therapeutic Area
Therapeutic area intelligence for BiTE with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.